360 related articles for article (PubMed ID: 37095570)
1. Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells.
Glaser V; Flugel C; Kath J; Du W; Drosdek V; Franke C; Stein M; Pruß A; Schmueck-Henneresse M; Volk HD; Reinke P; Wagner DL
Genome Biol; 2023 Apr; 24(1):89. PubMed ID: 37095570
[TBL] [Abstract][Full Text] [Related]
2. Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors.
Webber BR; Lonetree CL; Kluesner MG; Johnson MJ; Pomeroy EJ; Diers MD; Lahr WS; Draper GM; Slipek NJ; Smeester BA; Lovendahl KN; McElroy AN; Gordon WR; Osborn MJ; Moriarity BS
Nat Commun; 2019 Nov; 10(1):5222. PubMed ID: 31745080
[TBL] [Abstract][Full Text] [Related]
3. A versatile system for rapid multiplex genome-edited CAR T cell generation.
Ren J; Zhang X; Liu X; Fang C; Jiang S; June CH; Zhao Y
Oncotarget; 2017 Mar; 8(10):17002-17011. PubMed ID: 28199983
[TBL] [Abstract][Full Text] [Related]
4. Expanding the editable genome and CRISPR-Cas9 versatility using DNA cutting-free gene targeting based on in trans paired nicking.
Chen X; Tasca F; Wang Q; Liu J; Janssen JM; Brescia MD; Bellin M; Szuhai K; Kenrick J; Frock RL; Gonçalves MAFV
Nucleic Acids Res; 2020 Jan; 48(2):974-995. PubMed ID: 31799604
[TBL] [Abstract][Full Text] [Related]
5. Review: Sustainable Clinical Development of CAR-T Cells - Switching From Viral Transduction Towards CRISPR-Cas Gene Editing.
Wagner DL; Koehl U; Chmielewski M; Scheid C; Stripecke R
Front Immunol; 2022; 13():865424. PubMed ID: 35784280
[TBL] [Abstract][Full Text] [Related]
6. Genome Editing in CAR-T Cells Using CRISPR/Cas9 Technology.
Andreu-Saumell I; Rodriguez-Garcia A; Guedan S
Methods Mol Biol; 2024; 2748():151-165. PubMed ID: 38070114
[TBL] [Abstract][Full Text] [Related]
7. Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies.
Maganti HB; Kirkham AM; Bailey AJM; Shorr R; Kekre N; Pineault N; Allan DS
Cytotherapy; 2022 Apr; 24(4):405-412. PubMed ID: 35039239
[TBL] [Abstract][Full Text] [Related]
8. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing.
Dimitri A; Herbst F; Fraietta JA
Mol Cancer; 2022 Mar; 21(1):78. PubMed ID: 35303871
[TBL] [Abstract][Full Text] [Related]
9. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.
Ren J; Liu X; Fang C; Jiang S; June CH; Zhao Y
Clin Cancer Res; 2017 May; 23(9):2255-2266. PubMed ID: 27815355
[No Abstract] [Full Text] [Related]
10. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
[TBL] [Abstract][Full Text] [Related]
11. High-efficiency of genetic modification using CRISPR/Cpf1 system for engineered CAR-T cell therapy.
Ding R; Chao CC; Gao Q
Methods Cell Biol; 2022; 167():1-14. PubMed ID: 35152989
[TBL] [Abstract][Full Text] [Related]
12. Long Terminal Repeat CRISPR-CAR-Coupled "Universal" T Cells Mediate Potent Anti-leukemic Effects.
Georgiadis C; Preece R; Nickolay L; Etuk A; Petrova A; Ladon D; Danyi A; Humphryes-Kirilov N; Ajetunmobi A; Kim D; Kim JS; Qasim W
Mol Ther; 2018 May; 26(5):1215-1227. PubMed ID: 29605708
[TBL] [Abstract][Full Text] [Related]
13. Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL.
Diorio C; Murray R; Naniong M; Barrera L; Camblin A; Chukinas J; Coholan L; Edwards A; Fuller T; Gonzales C; Grupp SA; Ladd A; Le M; Messana A; Musenge F; Newman H; Poh YC; Poulin H; Ryan T; Shraim R; Tasian SK; Vincent T; Young L; Zhang Y; Ciaramella G; Gehrke J; Teachey DT
Blood; 2022 Aug; 140(6):619-629. PubMed ID: 35560156
[TBL] [Abstract][Full Text] [Related]
14. Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy.
Naeem M; Hazafa A; Bano N; Ali R; Farooq M; Razak SIA; Lee TY; Devaraj S
Life Sci; 2023 Mar; 316():121409. PubMed ID: 36681183
[TBL] [Abstract][Full Text] [Related]
15. Comparison of gene editing efficiencies of CRISPR/Cas9 and TALEN for generation of MSTN knock-out cashmere goats.
Zhang J; Liu J; Yang W; Cui M; Dai B; Dong Y; Yang J; Zhang X; Liu D; Liang H; Cang M
Theriogenology; 2019 Jul; 132():1-11. PubMed ID: 30981084
[TBL] [Abstract][Full Text] [Related]
16. Gene Editing With TALEN and CRISPR/Cas in Rice.
Bi H; Yang B
Prog Mol Biol Transl Sci; 2017; 149():81-98. PubMed ID: 28712502
[TBL] [Abstract][Full Text] [Related]
17. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
18. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.
Eyquem J; Mansilla-Soto J; Giavridis T; van der Stegen SJ; Hamieh M; Cunanan KM; Odak A; Gönen M; Sadelain M
Nature; 2017 Mar; 543(7643):113-117. PubMed ID: 28225754
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy.
Liu X; Zhao Y
Curr Res Transl Med; 2018 May; 66(2):39-42. PubMed ID: 29691200
[TBL] [Abstract][Full Text] [Related]
20. Detection and Modulation of DNA Translocations During Multi-Gene Genome Editing in T Cells.
Bothmer A; Gareau KW; Abdulkerim HS; Buquicchio F; Cohen L; Viswanathan R; Zuris JA; Marco E; Fernandez CA; Myer VE; Cotta-Ramusino C
CRISPR J; 2020 Jun; 3(3):177-187. PubMed ID: 32584143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
